Please login to the form below

Not currently logged in
Email:
Password:

trial failure

This page shows the latest trial failure news and features for those working in and with pharma, biotech and healthcare.

J&J’s Invokana first SGLT2 to show kidney disease benefits

J&J’s Invokana first SGLT2 to show kidney disease benefits

Results from the CREDENCE study, which evaluated type 2 diabetes patients with chronic kidney disease, showed that those taking the once-daily pill had a 30% lower risk of kidney failure, ... The trial puts Invokana one step ahead of rivals, such as

Latest news

  • Undeterred by aducanumab failure, Eisai and Biogen plough on Undeterred by aducanumab failure, Eisai and Biogen plough on

    Investors sceptical, though mechanism different. Mere hours after reporting the failure of aducanumab in Alzheimer’s disease, Eisai has cued up a phase 3 trial of BAN2401, another amyloid-targeted drug. ... BAN2401 has been seen as something of an

  • Amgen, Servier heart failure drug clears trial hurdle Amgen, Servier heart failure drug clears trial hurdle

    It is the most common form of heart failure. The trial’s primary endpoint is time-to-cardiovascular death or first heart-failure event, whichever occurs first. ... Amgen recently started phase 1 trials of another Cytokinetics-developed heart failure

  • AZ signs $20m deal with Seres for microbiome project AZ signs $20m deal with Seres for microbiome project

    the last couple of years after a mid-stage trial failure. ... SER-401 is already in a phase 1b trial in collaboration with MD Anderson Cancer Centre, sponsored by the Parker Institute for Cancer Immunotherapy, to see if the microbiome agent can

  • Amgen, Servier start second phase 3 trial of heart failure hope Amgen, Servier start second phase 3 trial of heart failure hope

    Treatment is one of few in underserved area. Amgen and Servier have decided to run a second phase 3 trial of omecamtiv mecarbil in heart failure, as their first pivotal study ... The new trial – dubbed METEORIC-HF – will compare omecamtiv to placebo

  • US, EU regulators back rapid reviews of AZ’s RSV med US, EU regulators back rapid reviews of AZ’s RSV med

    The new designations have been awarded on the strength of top-line data from a phase 2b trial of MEDI8897 which showed the drug was able to achieve a significant reduction ... Another rival, Regeneron’s antibody suptavumab (REGN2222), was dropped from

More from news
Approximately 26 fully matching, plus 60 partially matching documents found.

Latest Intelligence

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    Avoiding failure. By taking this approach to research, it's possible to avoid one of the major pitfalls facing pharma today – the high cost of late-stage trial failure. ... Particularly when we have high failure rates in late stages in clinical studies,

  • Customer valuation in pharma Customer valuation in pharma

    Multiple studies have pegged the probability of clinical trial success at between 13-20 per cent. ... This estimate has remained constant over decades. Among the major reasons for clinical trial failure are problems that rest squarely in the domain of

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Alzheimer's: the numbers we cannot forget

    This is one of the highest clinical trial failure rates in healthcare. ... Failures in these trials have been associated with lack of efficacy, excessive side effects, or challenges in trial execution; leaving patients and HCPs with 5 therapies to choose

  • A forward march for adaptive designs

    For example, poor dose selection in phase II is frequently cited as one of the top causes of late-stage clinical trial failure. ... As such, it has prioritised phase II/III adaptive trial designs as well as other types of study.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics